Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Physiomics ( (GB:PYC) ) is now available.
Physiomics plc has secured a new contract with a South Korean clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates and immuno-oncology therapies for cancer. The project, worth up to £66,600, will see Physiomics apply PK/PD modelling and simulation to guide dosing decisions for one of the client’s clinical assets, with work starting immediately and expected to complete within two months.
The mandate broadens Physiomics’ international client base and underscores its strategy of expanding into markets further afield, while highlighting the growing role of advanced quantitative modelling in de-risking oncology drug development. Management framed the win as validation of the company’s capabilities in providing data-driven insights that enhance decision-making for innovative cancer therapies at a critical clinical stage.
The most recent analyst rating on (GB:PYC) stock is a Hold with a £0.46 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Neutral.
The score is held back primarily by weak financial performance—persistent losses and ongoing cash burn despite a debt-free balance sheet and a 2025 revenue rebound. Technicals are supportive with price above major moving averages, but overbought signals raise near-term risk. Valuation remains constrained by negative earnings and no dividend support.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a UK-based mathematical modelling, data science and biostatistics specialist focused on supporting biotech and pharmaceutical companies in developing new therapeutics and personalised medicine. Leveraging computational tools, bespoke models and its proprietary Virtual Tumour technology, it helps streamline drug development across discovery, pre-clinical and clinical stages for clients including Merck KGaA, Astellas and Bicycle Therapeutics.
Average Trading Volume: 6,114,416
Technical Sentiment Signal: Sell
Current Market Cap: £1.52M
See more data about PYC stock on TipRanks’ Stock Analysis page.